Theodore J. Theophilos
President chez Lurie Holdings, Inc.
Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Damon C. Torres | M | - |
Robocast , Inc.
 Robocast , Inc. Internet Software/ServicesTechnology Services Robocast, Inc. is a company that licenses its methods and technologies to major companies. The company is based in New York, NY. The company's methods and technologies allow users to Play The Web®, improve usability, and add safety measures. It was founded by Damon C. Torres, who has been the CEO since incorporation. | 27 ans |
| Ann Lurie | F | - |
Lurie Holdings, Inc.
 Lurie Holdings, Inc. Investment ManagersFinance Lurie Holdings Inc (Lurie Holdings) is a venture capital subsidiary of Ann & Robert H. Lurie Family Foundation founded in 1995. The firm is headquartered in Chicago, Illinois. | - |
| Fred Eshelman | M | 76 |
Innocrin Pharmaceuticals, Inc.
 Innocrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC. | - |
| Douglas Reed | M | 70 |
Innocrin Pharmaceuticals, Inc.
Innocrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC.
Viamet Pharmaceuticals, Inc.
 Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | 17 ans |
| Andrew von Eschenbach | M | 82 |
Innocrin Pharmaceuticals, Inc.
Innocrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC.
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | 13 ans |
| Jeffrey Edwards | M | 63 |
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | - |
| Benjamin Lurie | M | 41 |
Robocast , Inc.
Robocast , Inc. Internet Software/ServicesTechnology Services Robocast, Inc. is a company that licenses its methods and technologies to major companies. The company is based in New York, NY. The company's methods and technologies allow users to Play The Web®, improve usability, and add safety measures. It was founded by Damon C. Torres, who has been the CEO since incorporation. | 2 ans |
| Mark Slezak | M | 65 |
Lurie Holdings, Inc.
Lurie Holdings, Inc. Investment ManagersFinance Lurie Holdings Inc (Lurie Holdings) is a venture capital subsidiary of Ann & Robert H. Lurie Family Foundation founded in 1995. The firm is headquartered in Chicago, Illinois. | 28 ans |
| Rick S. Kent | M | 74 |
Innocrin Pharmaceuticals, Inc.
Innocrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC. | - |
| Dennis Dougherty | M | 76 |
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | - |
| S. Torres | M | 61 |
Innocrin Pharmaceuticals, Inc.
Innocrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC. | - |
| Robert J. Schotzinger | M | 63 |
Innocrin Pharmaceuticals, Inc.
Innocrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC. | - |
| Bill T. White | M | - |
Lurie Holdings, Inc.
Lurie Holdings, Inc. Investment ManagersFinance Lurie Holdings Inc (Lurie Holdings) is a venture capital subsidiary of Ann & Robert H. Lurie Family Foundation founded in 1995. The firm is headquartered in Chicago, Illinois. | 24 ans |
| Adrian Howd | M | 52 |
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | - |
| Michal Silverberg | F | 48 |
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | - |
| Volker Herrmann | M | - |
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | 9 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Thomas W. Oliva | M | 66 |
Moore Wallace, Inc.
 Moore Wallace, Inc. Commercial Printing/FormsCommercial Services Moore Wallace, Inc. provides solutions in commercial printing, forms and labels, direct mail, financial printing, print fulfillment, business communication outsourcing, logistics, online services, digital photography, and content and database management | 2 ans |
| Gerard Jacobs | M | 68 |
The University of Chicago Law School
| 3 ans |
| Gail P. Runnfeldt | F | - |
The University of Chicago Law School
| 3 ans |
| Philip G. Hampton | M | - |
The University of Chicago Law School
| 3 ans |
| Alan D. Smith | M | - |
The University of Chicago Law School
| 3 ans |
| David A. Kessler | M | 72 |
The University of Chicago Law School
| 3 ans |
| Jonathan H. Lemberg | M | - |
The University of Chicago Law School
| 5 ans |
| William A. von Hoene | M | 70 |
The University of Chicago Law School
| 3 ans |
| Stewart M. Landefeld | M | 69 |
The University of Chicago Law School
| 3 ans |
| Mark Fukunaga | M | 68 |
The University of Chicago Law School
| 3 ans |
| Darryl M. Bradford | M | 68 |
The University of Chicago Law School
| 3 ans |
| Andrew M. Rosenfield | M | 72 |
The University of Chicago Law School
| 3 ans |
| Christopher Loomis Baker | M | 66 |
The University of Chicago Law School
| 4 ans |
| David Godden Dietze | M | 68 |
The University of Chicago Law School
| 3 ans |
| Bryant B. Edwards | M | 69 |
The University of Chicago Law School
| 3 ans |
| Mark Angelson | M | 73 |
Moore Wallace, Inc.
Moore Wallace, Inc. Commercial Printing/FormsCommercial Services Moore Wallace, Inc. provides solutions in commercial printing, forms and labels, direct mail, financial printing, print fulfillment, business communication outsourcing, logistics, online services, digital photography, and content and database management | 1 ans |
| Robert G. Burton | M | 48 |
Moore Wallace, Inc.
Moore Wallace, Inc. Commercial Printing/FormsCommercial Services Moore Wallace, Inc. provides solutions in commercial printing, forms and labels, direct mail, financial printing, print fulfillment, business communication outsourcing, logistics, online services, digital photography, and content and database management | 2 ans |
| Lee Shapiro | M | 68 |
The University of Chicago Law School
| 3 ans |
| Debra Cafaro | F | 66 |
The University of Chicago Law School
| 3 ans |
| James Sulat | M | 73 |
Moore Wallace, Inc.
Moore Wallace, Inc. Commercial Printing/FormsCommercial Services Moore Wallace, Inc. provides solutions in commercial printing, forms and labels, direct mail, financial printing, print fulfillment, business communication outsourcing, logistics, online services, digital photography, and content and database management | 1 ans |
| Harry R. Vinson | M | 63 |
Moore Wallace, Inc.
Moore Wallace, Inc. Commercial Printing/FormsCommercial Services Moore Wallace, Inc. provides solutions in commercial printing, forms and labels, direct mail, financial printing, print fulfillment, business communication outsourcing, logistics, online services, digital photography, and content and database management | 1 ans |
| Barry Zubrow | M | 70 |
The University of Chicago Law School
| 3 ans |
| Frank S. Plimpton | M | 68 |
The University of Chicago Law School
| 3 ans |
| Richard Todd Sansone | M | 58 |
Moore Wallace, Inc.
Moore Wallace, Inc. Commercial Printing/FormsCommercial Services Moore Wallace, Inc. provides solutions in commercial printing, forms and labels, direct mail, financial printing, print fulfillment, business communication outsourcing, logistics, online services, digital photography, and content and database management | 1 ans |
| Thomas Quinlan | M | 61 |
Moore Wallace, Inc.
Moore Wallace, Inc. Commercial Printing/FormsCommercial Services Moore Wallace, Inc. provides solutions in commercial printing, forms and labels, direct mail, financial printing, print fulfillment, business communication outsourcing, logistics, online services, digital photography, and content and database management | 4 ans |
| Dean Cherry | M | 63 |
Moore Wallace, Inc.
Moore Wallace, Inc. Commercial Printing/FormsCommercial Services Moore Wallace, Inc. provides solutions in commercial printing, forms and labels, direct mail, financial printing, print fulfillment, business communication outsourcing, logistics, online services, digital photography, and content and database management | 3 ans |
| John C. Lorentzen | M | - |
The University of Chicago Law School
| 3 ans |
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| Etats-Unis | 35 | 81,40% |
| Canada | 8 | 18,60% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Theodore J. Theophilos
- Réseau Personnel
